Biopharmaceutical News and Research

RSS

Johnson & Johnson's sales increase 5.1% to $18.5 billion in Q3 2014

Johnson & Johnson today announced sales of $18.5 billion for the third quarter of 2014, an increase of 5.1% as compared to the third quarter of 2013. Operational results increased 5.8% and the negative impact of currency was 0.7%. Domestic sales increased 11.6%. International sales decreased 0.3%, reflecting operational growth of 1.0% and a negative currency impact of 1.3%.

14 Oct 2014

OBN, ABPI sign MoU to build a better public profile

13 October 2014, London and Oxford: The ABPI, which represents large, medium and small innovative research-based biopharmaceutical companies in the UK and OBN, the membership organisation that brings together the UK's emerging life sciences companies, corporate partners and investors are delighted to announce their commitment to working together under a Memorandum of Understanding (MoU).

13 Oct 2014

Maker of experimental Ebola drug scales up

The manufacturer of the experimental Ebola drug ZMapp says it has put other business on hold since August to boost production of the medication. Meanwhile, news outlets look at the government's authority to screen airline travelers, the House action to release additional funding for disease-fighting efforts and the Dallas hospital's defense of its treatment of the West African man who died of the disease this week.

12 Oct 2014

GE Healthcare-Glaxo Smith Kline deal to create force in cancer testing

A recently announced deal between GE Healthcare-subsidiary Clarient and Glaxo Smith Kline will create a force in cancer testing, according to Kalorama Information. The healthcare market research publisher tracks companion products, and says that the two entities will form a multi-purpose, data analytics- and companion diagnostics-driven network of laboratories. Kalorama Information recently released a market study, Companion Diagnostics Market, for companion diagnostics such as the drug-test combinations envisioned in this deal.

9 Oct 2014

CytRx begins Phase 1b trial of aldoxorubicin plus gemcitabine in patients with metastatic solid tumors

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced the initiation of enrollment in an open-label Phase 1b clinical trial designed to investigate the preliminary safety and activity of aldoxorubicin plus gemcitabine in subjects with metastatic solid tumors.

9 Oct 2014

Endo International enters into definitive agreement to acquire Auxilium Pharmaceuticals

Endo International plc and Auxilium Pharmaceuticals, Inc. today announced that they have entered into a definitive agreement under which Endo will acquire all of the outstanding shares of common stock of Auxilium for a per share consideration of $33.25 in a cash and stock transaction.

9 Oct 2014

Ruthigen begins Phase 1/2 clinical trial of RUT58-60

Ruthigen Inc., a biopharmaceutical company focused on pioneering new therapies to improve patient outcomes and reduce healthcare costs associated with infections related to post-operative invasive procedures, announces the initiation of a Phase 1/2 clinical trial to evaluate the safety, tolerability, and potential efficacy of its lead drug candidate, RUT58-60, for use as an adjunct to systemic antibiotics in abdominal surgery.

8 Oct 2014

OBN, EMIG call on the UK government to allocate additional funding to support BMC programme

OBN and EMIG - organisations with a combined membership of approximately 570 emerging R&D companies in biotechnology and medical technology, and established small and mid-sized biopharmaceutical firms, respectively - have called on the UK government to allocate additional funding to support the industrial component of Innovate UK's Biomedical Catalyst (BMC).

8 Oct 2014

Obama administration announces plans to step up airport screening for Ebola virus

Though President Barack Obama did not say exactly how screening procedures would change, the director of the Centers for Disease Control and Prevention said officials would consider a variety of options.

8 Oct 2014

Pinnacle initiates pivotal Phase 3 trial in Germany for rare form of bile duct cancer

Pinnacle Biologics, Inc., a subsidiary of Concordia Healthcare Corp., announced today the initiation of the pivotal Phase 3 trial (OPUS) in Germany for a rare form of bile duct cancer for which there is currently no acceptable therapy.

7 Oct 2014

Ardelyx announces positive Phase 2b results for tenapanor in IBS-C patients

Ardelyx, Inc., a clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal and metabolic diseases, today announced positive results from its 371 patient Phase 2b clinical trial evaluating tenapanor in patients with constipation-predominant irritable bowel syndrome (IBS-C).

1 Oct 2014

Johnson & Johnson inks definitive deal to acquire Alios BioPharma

Johnson & Johnson today announced a definitive agreement to acquire Alios BioPharma, Inc., a privately held clinical stage biopharmaceutical company focused on developing therapies for viral diseases, for approximately $1.75 billion in cash.

30 Sep 2014

CytRx begins aldoxorubicin Phase 2b clinical trial in patients with extensive-stage SCLC

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced the initiation of a global Phase 2b clinical trial evaluating aldoxorubicin compared to topotecan in subjects with extensive-stage small cell lung cancer (SCLC) who have relapsed or were refractory to prior chemotherapy.

30 Sep 2014

Arisaph Pharmaceuticals receives STTR grants to develop cancer drug candidates

Arisaph Pharmaceuticals, Inc., a privately held biopharmaceutical company focused on discovery and development of novel therapies for cardiometabolic diseases and cancer, announced today that it has been awarded a phase II Small Business Technology Transfer (STTR) grant and a supplemental phase I grant, both from the National Cancer Institute of the National Institutes of Health.

29 Sep 2014

Galmed Pharmaceuticals purchases EndoPAT devices, accessories from Itamar Medical

Galmed Pharmaceuticals Ltd. ("Galmed"), a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral medication for the treatment of liver diseases and cholesterol gallstones, announced today that it purchased 60 EndoPAT™ devices and accessories from Itamar Medical Ltd.

29 Sep 2014

Tianyin Pharmaceutical's Qionglai Facility completes official GMP site visit by CFDA

Tianyin Pharmaceutical Co., Inc., a pharmaceutical company that specializes in patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API), today announced that its Qionglai Facility (QLF) has successfully completed the official site visit by the China Food & Drug Administration's (CFDA) for its Good Manufacturing Practice (GMP) certification.

29 Sep 2014

FDA grants multiple Orphan Drug Designations for CytRx's aldoxorubicin

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced that the U.S. Food and Drug Administration has granted multiple Orphan Drug Designations for the Company's lead drug candidate, aldoxorubicin, in three indications: glioblastoma multiforme (GBM), small cell lung cancer and ovarian cancer.

29 Sep 2014

Daiichi Sankyo, Ambit Biosciences enter into definitive merger agreement

Daiichi Sankyo Company, Ltd. (hereinafter Daiichi Sankyo) and Ambit Biosciences, jointly announced today that they have entered into a definitive merger agreement under which Daiichi Sankyo will acquire all of the outstanding common stock of Ambit Biosciences for $15 per share in cash through a tender offer followed by a merger with a subsidiary of Daiichi Sankyo, or approximately $315 million on a fully diluted basis.

29 Sep 2014

EMD Serono declares winners of first Grant for Oncology Innovation

EMD Serono, the biopharmaceutical division of Merck KGaA, Darmstadt, Germany, today announced the winners of the first Grant for Oncology Innovation (GOI), who will receive grants totaling $1.3 million.

27 Sep 2014

Research report on biopharmaceutical and vaccine manufacturing markets

The total biopharmaceutical manufacturing market is growing, according to Kalorama Information's report, Biopharmaceutical and Vaccine Production Markets.

24 Sep 2014

Biopharmaceutical News and Research

Johnson & Johnson's sales increase 5.1% to $18.5 billion in Q3 2014

OBN, ABPI sign MoU to build a better public profile

Maker of experimental Ebola drug scales up

GE Healthcare-Glaxo Smith Kline deal to create force in cancer testing

CytRx begins Phase 1b trial of aldoxorubicin plus gemcitabine in patients with metastatic solid tumors

Endo International enters into definitive agreement to acquire Auxilium Pharmaceuticals

Ruthigen begins Phase 1/2 clinical trial of RUT58-60

OBN, EMIG call on the UK government to allocate additional funding to support BMC programme

Obama administration announces plans to step up airport screening for Ebola virus

Pinnacle initiates pivotal Phase 3 trial in Germany for rare form of bile duct cancer

Ardelyx announces positive Phase 2b results for tenapanor in IBS-C patients

Johnson & Johnson inks definitive deal to acquire Alios BioPharma

CytRx begins aldoxorubicin Phase 2b clinical trial in patients with extensive-stage SCLC

Arisaph Pharmaceuticals receives STTR grants to develop cancer drug candidates

Galmed Pharmaceuticals purchases EndoPAT devices, accessories from Itamar Medical

Tianyin Pharmaceutical's Qionglai Facility completes official GMP site visit by CFDA

FDA grants multiple Orphan Drug Designations for CytRx's aldoxorubicin

Daiichi Sankyo, Ambit Biosciences enter into definitive merger agreement

EMD Serono declares winners of first Grant for Oncology Innovation

Research report on biopharmaceutical and vaccine manufacturing markets

Industry Focus - Biopharma eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News